Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open label intra-patient dose escalation study to evaluate safety and
tolerability, pharmacokinetics, and pharmacodynamics of BPS804 in adults with osteogenesis
imperfecta (OI).
Pharmacodynamic effect will be determined by serological biomarkers and radiologic
assessments. In addition, tolerability and pharmacokinetics (PK) will be evaluated.